Rhythm Pharmaceuticals
RYTM
97 hedge funds and large institutions have $626M invested in Rhythm Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 29 increasing their positions, 35 reducing their positions, and 15 closing their positions.
171% more call options, than puts
Call options by funds: $715K | Put options by funds: $264K
0.9% more ownership
Funds ownership: 94.57% → 95.47% (+0.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 105 → 97 (-8)
17% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 35
31% less capital invested
Capital invested by funds: $905M → $626M (-$279M)
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$28.1M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.49M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$2.57M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.29M |
| 5 |
Millennium Management
New York
|
+$918K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$11.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.87M |
| 3 |
Morgan Stanley
New York
|
-$3.68M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.09M |
| 5 |
ACM
Altium Capital Management
New York
|
-$2.05M |
RYTM Hedge Fund Activity: Q3 2021 in Review
97 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q3 2021, worth a combined $626M — down 31% from $905M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of RYTM and 7 opened new positions — a net loss of 8 holders — while 35 trimmed existing stakes and 29 added.
The largest buyer was Goldman Sachs, adding an estimated $28.1M. The largest seller was Janus Henderson Group, cutting an estimated $11.4M.
- 97 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q3 2021, down from 105 in Q2 2021.
- Funds reported $626M of Rhythm Pharmaceuticals stock for Q3 2021, down 31% quarter-over-quarter.
- 7 funds opened new Rhythm Pharmaceuticals positions in Q3 2021 and 15 closed out, a net change of -8 holders.
- The largest Rhythm Pharmaceuticals buyer in Q3 2021 was Goldman Sachs, an estimated $28.1M added.
- The largest Rhythm Pharmaceuticals seller in Q3 2021 was Janus Henderson Group, an estimated $11.4M sold.
Based on aggregated 13F filings for Q3 2021.